Thyrocare Technologies Ltd Stock Price Today (NSE: THYROCARE)
Fundamental Score
Thyrocare Technologies Ltd Share Price Live NSE/BSE & Institutional Fundamental Analysis
Thyrocare Technologies Ltd share price today is ₹420.35, up +0.00% on NSE/BSE as of 17 February 2026. Thyrocare Technologies Ltd (THYROCARE) is a Mid-cap company in the Healthcare Service Provider sector with a market capitalisation of ₹7.72K (Cr). The 52-week high for THYROCARE share price is ₹N/A and the 52-week low is ₹N/A. At a P/E ratio of 60.48x, THYROCARE is currently trading above its industry average P/E of 39.28x. The company has a Return on Equity (ROE) of 16.15% and a debt-to-equity ratio of 0.05.
Thyrocare Technologies Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Thyrocare Technologies Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Thyrocare Technologies Share Price Analysis: A ROCE Focused Perspective
The healthcare service provider industry, while generally recession-resistant, faces increasing pressure to optimize Return on Capital Employed (ROCE) due to escalating infrastructure costs and evolving regulatory landscapes. This analysis delves into the financial health of Thyrocare Technologies Ltd, focusing specifically on its ROCE efficiency. Currently, the Thyrocare Technologies share price sits at ₹405.6499938964844, with a Price-to-Earnings (PE) ratio of 60.48 and a ROCE of 24.78%. This analysis is part of a comprehensive 80-parameter fundamental audit, verified by Sweta Mishra, focusing on key financial ratios and comparative performance.
A ROCE of 24.78% signifies that Thyrocare Technologies is generating a substantial return on the capital it employs. This level of profitability, when sustained, can contribute significantly to the company’s economic moat. A high ROCE suggests efficient capital allocation and potentially strong pricing power, which helps defend against competitors and creates long-term shareholder value. However, it's important to assess the sustainability of this ROCE, considering factors like competitive pressures, technological advancements, and changes in healthcare regulations.
Relative to its peers, such as
Suraksha Diagnostic Ltd, the management quality at Thyrocare Technologies is a crucial factor influencing its ROCE. While quantitative data provides a snapshot of financial performance, the ability of the management team to strategically allocate capital, adapt to market changes, and maintain operational efficiency plays a vital role in sustaining high returns. Further investigation into management's track record and strategic initiatives is necessary to form a more complete picture.While the PE ratio of 60.48 suggests that the market has high expectations for future earnings growth, it is vital to consider whether the current Thyrocare Technologies share price adequately reflects the risks associated with maintaining such a high ROCE in the long term. Factors impacting the future ROCE include efficiency in lab operations, test menu, the effectiveness of its distribution network, competition from existing and new players and the ability to maintain or reduce costs to remain competitive.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Thyrocare Technologies Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of THYROCARE across key market metrics for learning purposes.
Positive Indicators
9 factors identified
Strong Return on Equity (16.15%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (24.78%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (29.95%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Robust Profit Growth (79.94%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (22.09%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Conservative Debt Levels (D/E: 0.05)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (71.48x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Strong Cash Generation (₹532.83 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (71.05%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Risk Factors
4 factors identified
Premium Valuation Risk (P/E: 60.48x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Weak Earnings Growth (-0.71% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Stagnant Profit Growth (-0.64% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity.
High Share Pledging Risk (85.84%)
Observation: Significant promoter share pledging creates potential overhang.
Analysis: High pledging levels may create selling pressure during market downturns.
Thyrocare Technologies Ltd Financial Statements
Comprehensive financial data for Thyrocare Technologies Ltd including income statement, balance sheet and cash flow
About THYROCARE (Thyrocare Technologies Ltd)
Thyrocare Technologies Ltd (THYROCARE) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Healthcare Service Provider sector with a current market capitalisation of ₹7.72K (Cr). Thyrocare Technologies Ltd has delivered a Return on Equity (ROE) of 16.15% and a ROCE of 24.78%. The debt-to-equity ratio stands at 0.05, reflecting the company's capital structure. Investors tracking THYROCARE share price can monitor key metrics including P/E ratio, promoter holding of 71.05%, and quarterly earnings growth.
Company Details
Key Leadership
Corporate Events
Latest News
THYROCARE Share Price: Frequently Asked Questions
What is the current share price of Thyrocare Technologies Ltd (THYROCARE)?
As of 17 Feb 2026, 10:25 am IST, Thyrocare Technologies Ltd share price is ₹420.35. The THYROCARE stock has a market capitalisation of ₹7.72K (Cr) on NSE/BSE.
Is THYROCARE share price Overvalued or Undervalued?
THYROCARE share price is currently trading at a P/E ratio of 60.48x, compared to the industry average of 39.28x. Based on this relative valuation, the Thyrocare Technologies Ltd stock appears to be Overvalued against its sector peers.
What is the 52-week high and low of THYROCARE share price?
The 52-week high of THYROCARE share price is ₹N/A and the 52-week low is ₹N/A.
What factors affect the Thyrocare Technologies Ltd share price?
Key factors influencing THYROCARE share price include quarterly earnings growth (Sales Growth: 22.09%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Thyrocare Technologies Ltd a good stock for long-term investment?
Thyrocare Technologies Ltd shows a 5-year Profit Growth of -0.64% and an ROE of 16.15%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.05 before investing in THYROCARE shares.
How does Thyrocare Technologies Ltd compare with its industry peers?
Thyrocare Technologies Ltd competes with major peers in the Healthcare Service Provider. Investors should compare THYROCARE share price P/E of 60.48x and ROE of 16.15% against the industry averages to determine competitive standing.
What is the P/E ratio of THYROCARE and what does it mean?
THYROCARE share price has a P/E ratio of 60.48x compared to the industry average of 39.28x. Investors pay ₹60 for every ₹1 of annual earnings.
How is THYROCARE performing according to Bull Run's analysis?
THYROCARE has a Bull Run fundamental score of 40.5/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does THYROCARE belong to?
THYROCARE operates in the Healthcare Service Provider industry. This classification helps understand the competitive landscape and sector-specific trends affecting Thyrocare Technologies Ltd share price.
What is Return on Equity (ROE) and why is it important for THYROCARE?
THYROCARE has an ROE of 16.15%, which indicates excellent management efficiency. ROE measures how efficiently Thyrocare Technologies Ltd generates profits from shareholders capital.
How is THYROCARE debt-to-equity ratio and what does it indicate?
THYROCARE has a debt-to-equity ratio of 0.05, which indicates conservative financing with low financial risk.
What is THYROCARE dividend yield and is it a good dividend stock?
THYROCARE offers a dividend yield of 1.44%, meaning you receive ₹1.44 annual dividend for every ₹100 invested in Thyrocare Technologies Ltd shares.
How has THYROCARE share price grown over the past 5 years?
THYROCARE has achieved 5-year growth rates of: Sales Growth 9.62%, Profit Growth -0.64%, and EPS Growth -0.71%.
What is the promoter holding in THYROCARE and why does it matter?
Promoters hold 71.05% of THYROCARE shares, with 85.84% pledged. High promoter holding often indicates strong management confidence in Thyrocare Technologies Ltd.
What is THYROCARE market capitalisation category?
THYROCARE has a market capitalisation of ₹7725 crores, placing it in the Mid-cap category.
How volatile is THYROCARE stock?
THYROCARE has a beta of N/A. A beta > 1 suggests the Thyrocare Technologies Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is THYROCARE operating profit margin trend?
THYROCARE has a 5-year average Operating Profit Margin (OPM) of 29.95%, indicating the company's operational efficiency.
How is THYROCARE quarterly performance?
Recent quarterly performance shows Thyrocare Technologies Ltd YoY Sales Growth of 22.09% and YoY Profit Growth of 79.94%.
What is the institutional holding pattern in THYROCARE?
THYROCARE has FII holding of 4.85% and DII holding of 13.47%. Significant institutional holding often suggests professional confidence in the Thyrocare Technologies Ltd stock.